EVGN · NASDAQ
Evogene (EVGN) Stock Price & Fundamentals
Evogene (EVGN) closed at $594.57 on Oct 9, 2026, up 0.14% from the previous close of $593.74.
Share price, past year
1Y +28.14%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $594.57 |
| Sep 30, 2026 | $604.65 |
| Aug 31, 2026 | $615.61 |
| Jul 31, 2026 | $595.39 |
| Jun 30, 2026 | $599.75 |
| May 29, 2026 | $576.04 |
| Apr 30, 2026 | $569.78 |
| Mar 31, 2026 | $573.86 |
| Feb 27, 2026 | $566.31 |
| Jan 30, 2026 | $537.12 |
| Dec 31, 2025 | $507.88 |
| Nov 28, 2025 | $473.69 |
| Oct 31, 2025 | $477.65 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 8.7M
- Dividend yield
- —
- 52-week range
- $459.97 – $635.07
Market cap, P/E and dividend yield aren't shown for Evogene yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US.
Financials
Evogene reported revenue of $3.85M for fiscal 2025, down 30.91% from fiscal 2024.
Evogene reported a net loss of $8.49M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $3.85M | −30.9% | −$8.49M | −220.2% | $1.08 | −$13.64M |
| FY2024ended Dec 31, 2024 | $5.58M | +87.0% | −$16.49M | −295.6% | −$2.90 | −$20.33M |
| FY2023ended Dec 31, 2023 | $2.98M | +78.0% | −$23.88M | −800.8% | −$5.20 | −$22.15M |
| FY2022ended Dec 31, 2022 | $1.68M | +80.1% | −$26.64M | −1,590.3% | −$6.44 | −$24.85M |
| FY2021ended Dec 31, 2021 | $930.00K | −10.6% | −$27.79M | −2,988.5% | −$0.69 | −$25.56M |
| FY2020ended Dec 31, 2020 | $1.04M | +38.1% | −$23.37M | −2,247.5% | −$0.83 | −$20.20M |
| FY2019ended Dec 31, 2019 | $753.00K | −56.9% | −$18.11M | −2,405.3% | — | −$18.57M |
| FY2018ended Dec 31, 2018 | $1.75M | −48.3% | −$20.76M | −1,188.2% | — | −$15.54M |
| FY2017ended Dec 31, 2017 | $3.38M | −48.3% | −$20.84M | −616.3% | — | −$16.52M |
| FY2016ended Dec 31, 2016 | $6.54M | — | −$19.59M | −299.6% | — | −$12.50M |
Company profile
- Name
- Evogene Ltd.
- Ticker
- EVGN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Agricultural Chemicals
- Headquarters
- 13 Gad Feinstein Street, Park Rehovot, Rehovot, L3 7638517
- Incorporated in
- L3
- Fiscal year ends
- December
- SEC CIK
- 0001574565
Recent SEC filings
- Mar 26, 2026
- Mar 27, 2025
- Mar 28, 2024
- Mar 30, 2023
- Mar 31, 2022
- Apr 2, 2021
- Apr 27, 2020
- Apr 29, 2019
Frequently asked questions
What is Evogene's stock price?
Evogene (EVGN) closed at $594.57 on Oct 9, 2026, up 0.14% from the previous close of $593.74.
How much revenue does Evogene make?
Evogene reported revenue of $3.85M for fiscal 2025, down 30.91% from fiscal 2024.
Sources and methodology
Fundamentals come from Evogene Ltd.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures